Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia

Phase 2 Completed 19 enrolled Ascenta Therapeutics

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label Phase 2 study to evaluate the safety and efficay of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Timeline

Start: 2006-01
Primary completion: 2007-11
Completion: 2007-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AT-101	Small molecule	80 mg	—
Background	Rituximab	Monoclonal antibody	375 mg/m2	—

Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia

Summary

Timeline

Drugs

Indications